In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Eisai licenses rights to Zonegran from Elan

Executive Summary

Elan Corp. PLC, the original licensee of North American and European rights to Dainippon Pharmaceutical's Zonegran, has transferred these rights to Eisai. Zonegran (zonisamide) is an FDA-approved drug to treat partial seizures in adult epileptic patients.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies